drugset
drugset / Trial / NCT05507606

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

NCT05507606 ↗

Phase 2 Unknown 50 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open-label, phase I clinical trial aimed to evaluate the efficacy and safety of Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated Patients With EGFR Mutation Advanced Non-squamous Non-Small Cell Lung Cancer With Concomitant Mutations.

Timeline

Start
2021-08-01
Primary completion
2023-08-01
Completion
2024-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg —
Subject Carboplatin Small molecule 5 unknown —
Subject Osimertinib Small molecule 80 mg —
Subject Pemetrexed Small molecule 500 mg/m2 —

Indications

non-small cell lung carcinoma